Pages that link to "Q55130362"
Jump to navigation
Jump to search
The following pages link to Daniel B Costa (Q55130362):
Displaying 50 items.
- Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis (Q26784085) (← links)
- Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer (Q27680966) (← links)
- Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer (Q27851588) (← links)
- A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response (Q27851728) (← links)
- Crizotinib in ROS1-rearranged non-small-cell lung cancer. (Q27853075) (← links)
- Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling (Q27853157) (← links)
- In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer (Q27853236) (← links)
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. (Q27853339) (← links)
- Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. (Q33788708) (← links)
- Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer. (Q33897022) (← links)
- EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications (Q33963199) (← links)
- Serum concentrations of Erlotinib at a dose of 25 mg daily. (Q34097177) (← links)
- β-catenin contributes to lung tumor development induced by EGFR mutations (Q34353437) (← links)
- Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib (Q34393558) (← links)
- Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer (Q34501607) (← links)
- KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma (Q34688751) (← links)
- Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities (Q35146927) (← links)
- Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. (Q35164218) (← links)
- De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors. (Q35164473) (← links)
- CCAAT/enhancer binding protein β is dispensable for development of lung adenocarcinoma. (Q35175264) (← links)
- Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer (Q35200541) (← links)
- Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases (Q35549714) (← links)
- Case series of treatment approaches in fit nonagenarians with stage IV non-small-cell lung cancer. (Q35667813) (← links)
- Patterns of care for non-small-cell lung cancer at an academic institution affiliated with a national cancer institute-designated cancer center. (Q35695893) (← links)
- A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia. (Q35921510) (← links)
- Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. (Q36044531) (← links)
- Diabetes mellitus as the presenting feature of extrahepatic cholangiocarcinoma in situ: case report and review of literature. (Q36067877) (← links)
- EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer. (Q36240964) (← links)
- Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice (Q36301400) (← links)
- Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M. (Q36427381) (← links)
- Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. (Q36491122) (← links)
- Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation. (Q36493522) (← links)
- Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers (Q36905639) (← links)
- Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas. (Q36927538) (← links)
- Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma (Q37037333) (← links)
- The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer (Q37085219) (← links)
- Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancer. (Q37238254) (← links)
- Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practice. (Q37238413) (← links)
- Treatment-related toxicities in a phase II trial of dasatinib in patients with squamous cell carcinoma of the lung (Q37241709) (← links)
- Alterations of tumor microenvironment by carbon monoxide impedes lung cancer growth (Q37269175) (← links)
- Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. (Q37379113) (← links)
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study (Q37606591) (← links)
- Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer (Q37626056) (← links)
- Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer (Q37638241) (← links)
- Molecular testing in lung cancer: the time is now. (Q37771888) (← links)
- Management and future directions in non-small cell lung cancer with known activating mutations (Q38214303) (← links)
- Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. (Q38409218) (← links)
- The Clinical Use of Genomic Profiling to Distinguish Intrapulmonary Metastases From Synchronous Primaries in Non-Small-Cell Lung Cancer: A Mini-Review (Q38441535) (← links)
- Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches (Q38653663) (← links)
- ALK translocation in non-small cell lung cancer with adenocarcinoma and squamous cell carcinoma markers. (Q41059959) (← links)